Back to results
US 9,540,317 B2Granted
Class- and isoform-specific HDAC inhibitors and uses thereof
AssigneesPresident and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
InventorsRalph Mazitschek, James E. Bradner
Life of this patent
Estimating the term…
Abstract
The present invention is drawn to compounds of Formula (I) below: and the pharmaceutically acceptable salts thereof, wherein R and R″ are defined herein. The compounds are useful inhibitors of histone deacetylases (HDAC).
Claims39
A compound of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- R is a cyclic or acyclic, substituted or unsubstituted aliphatic moiety;
- a cyclic or acyclic, substituted or unsubstituted heteroaliphatic moiety;
- a substituted or unsubstituted aryl moiety;
- or a substituted or unsubstituted heteroaryl moiety;
- and
- each occurrence of R″ is independently hydrogen, halogen, or C1-6alkyl.
4 more elements
A compound of Formula (II):
- or a pharmaceutically acceptable salt thereof, wherein:
- R is a cyclic or acyclic, substituted or unsubstituted aliphatic moiety;
- a cyclic or acyclic, substituted or unsubstituted heteroaliphatic moiety;
- a substituted or unsubstituted aryl moiety;
- or a substituted or unsubstituted heteroaryl moiety;
- and
- each occurrence of R″ is independently hydrogen, halogen, or C1-6alkyl.
4 more elements
Dependencies are inferred from the claim text.